- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Repligen Corp (RGEN)
| Open: | 8.6900 | Day's Range: | 8.5300 - 8.7700 | Volume: | 262,062 |
|---|---|---|---|---|---|
| Previous Close: | 8.7000 | 52wk Range: | 3.7200 - 9.6500 | 1-Yr Rtn: | +87.58% |
Key Statistics for RGEN
| Current P/E Ratio (ttm) | 17.2545 |
|---|---|
| Estimated P/E(12/2013) | 15.3750 |
| Relative P/E vs. SPX | 1.0602 |
| Earnings Per Share (USD) (ttm) | 0.4990 |
| Est. EPS (USD) (12/2013) | 0.5600 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 270.72 |
| Shares Outstanding (M) | 31.44 |
| 30 Day Average Volume | 408,566 |
| Price/Book (mrq) | 3.0954 |
| Price/Sale (ttm) | 4.0567 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/02/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for RGEN
Company Profile & Key Executives for RGEN
Repligen Corporation is a biotechnology company. The Company develops therapeutics for the treatment of diseases of the central nervous system. Repligen owns owns intellectual property on monoclonal antibody and antibody fusion products.
| Walter C HerlihyPresident/CEO | Jonathan I LieberCFO/Treasurer |
| William J KellyChief Accounting Officer | Daniel P WittSenior VP:Global Operations |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
RGEN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page